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Early detection of polyps or colorectal carcinoma can reduce colorectal carcinoma-associated deaths. Previous studies have
demonstrated raised serum levels of matrix metalloproteinase 9 (sMMP-9) in a range of cancers. The aim of this study was to
investigate the role of sMMP-9 levels in identifying colorectal neoplasia. Consenting patients donated a blood sample and were
assessed by proforma-led history and physical examination. Samples were analysed for sMMP-9 concentration (enzyme-linked
immuno-sorbant assay) and compared to final diagnoses. Logistic regression modelling determined independent factors associated
with neoplasia. A total of 365 patients were recruited of whom 300 were analysed, including 46 normal controls. A total of 27
significant adenomas and 63 malignancies were identified. The median sMMP-9 concentration was 443ngml
 1 (IQR: 219–782; mean:
546). Patients with neoplasia had significantly elevated sMMP-9 levels (Po0.001). Logistic regression modelling identified elevated
log(sMMP-9) as the most significant predictor of neoplasia (w
2¼38.33, Po0.001). Other significant factors were age, sex, smoking
history, abdominal pain and weight loss. The model accurately predicted neoplasia in 77.3% of cases. Sensitivity and specificity were
77.9 and 77.1%. sMMP-9 estimation can accurately stratify patient to low- or high-risk cohorts. Serum sampling is a potential means of
avoiding unnecessary colonoscopy and reducing patient anxiety, iatrogenic morbidity and mortality, and cost.
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Colorectal cancer remains the second commonest malignancy in
England and Wales and is the target of the newest national cancer
screening programme, which was officially launched in April 2006.
There are more than 30000 new cases of colorectal cancer each
year in the United Kingdom and about 16000 deaths, incurring an
annual expenditure of more than d300 million in surgical,
adjuvant, and palliative treatment (ONS, 2005; Macafee et al,
2006). Surgical advances have not improved the 5-year survival
rates in the last 20 years and though an early histopathological
stage at primary surgical resection correlates with increased
disease-free long-term survival, 50% of patients still present with
late-stage disease (Umpleby et al, 1984). Crude 5-year survival
rates are only 35% due to the late stage of presentation of most
cases (ONS, 2003). Resection of lesions in the premalignant stage
permits cure without risk of occult distant metastases, therefore
the detection of such early tumours is vital for a successful
screening programme. Polyp excision is important in reducing the
rate of progression to carcinoma in most individuals (Muto et al,
1975; Stryker et al, 1987). Excision of polyps and early tumours is
associated with a good prognosis, whereas treatment of invasive
carcinomas has a less favourable outcome (Dukes, 1932). There-
fore, early detection of polyps or colorectal carcinoma before
invasion into the surrounding mucosa represents the best hope of
reducing colorectal carcinoma-associated deaths.
The majority of investigations currently employed in the
assessment of patients with colorectal symptoms involve invasive
procedures, exposure to significant doses of ionising radiation, or
a combination of these. One or more techniques may be
sequentially used in individual assessments, with increased risk
accompanying multiple investigations.
While the risk of colonic perforation may be easily assumed by
the very nature of flexible endoscopic approaches, it also accounts
for morbidity in radiological procedures such as contrast radiology
in which the sequelae of such perforations may be exaggerated by
virtue of contrast media employed. Other risks include contrast
reactions and delayed effects of ionising radiation exposure, which
is cumulative and non-reversible. Clearly when there is commen-
surate benefit in the investigation, the excess risk may be
partly compensated as in the staging investigation, which may
follow a positive barium enema. Recent proposals suggest that
quantification of the increased lifetime risk of developing a
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sradiation-induced neoplasm should be imparted to patients prior
to exposure as part of a consent process (Picano, 2004). However,
it is clear that a non-invasive test, avoiding ionising radiation,
would be desirable.
Non-invasive faecal occult blood testing (FOBT) relies on
detection of the surrogate marker of degradation products of
haemoglobin. A number of factors limit its use including the
relatively poor acceptability of stool sampling and that the sought
tumour must bleed – not all colorectal neoplasms bleed, or may
only shed blood intermittently. Friability may be a late develop-
ment arising when other symptoms are apparent. Adenomatous
polyps bleed less than malignant lesions, accounting for the lower
sensitivity for polyps (30% compared to ca. 50% for carcinomas).
However data are available suggesting that use of FOBT detects
colorectal lesions at an earlier stage, and that screened lesions are
associated with survival benefits (Towler et al, 1998).
Analysis of serum samples for stratification of risk of colorectal
neoplasia is untested in the clinical setting. The ideal target moiety
is debatable and has centred on carcino embryonic antigen (CEA)
and non-specific inflammatory markers such as C-reactive protein,
erythrocyte sedimentation rate, and serum ferritin levels. While
CEA may boast a degree of specificity for malignancy, it is also
elevated in many diverse states including old age, obesity,
smoking, inflammatory lung disease, liver disease, and other
diseases of the digestive tract (Ruibal-Morell, 1992). Elevations in
CEA levels are also reported in non-colorectal malignancies,
including lung (74%) (Vincent and Chu, 1973; Dent et al, 1978),
breast (57%), oesophageal, gastric, and pancreatic carcinomas. It is
also more likely to be elevated in disseminated disease than in
locally confined (and hence surgically curable) lesions (Beatty
et al, 1979). Levels may decline with disease regression on
treatment with chemotherapy (Bates and Longo, 1987), but up to
10% of patients with falling levels exhibit progressive disease
(Kreiger et al, 1983).
Matrix metalloproteinases (MMPs) are zinc-dependent endo-
peptidases that catalyse the dissolution of the extracellular matrix
classified according to domain structure into collagenases, gelati-
nases, stromelysins, membrane-type, and others (Kleiner and Stetler-
Stevenson, 1999; Pei, 1999). The gelatinases, MMP-2 and MMP-9,
have been particularly implicated in tumour invasion and metastasis
formation (Poulsom et al, 1992; Parsons et al, 1998; Zeng et al, 1999).
The primary substrate for these enzymes is type IV collagen, a major
component of the basement membrane, which represents a
substantial barrier for tumour cell metastasis. Most MMPs are
secreted as zymogens and require activation through cleavage of a
pro-domain sequence located at the N terminus of the protein.
MMPs are elevated during physiological processes, such as
tissue remodelling during growth phases, pregnancy and partui-
tion, following injury and in pathological disease states, for
example chronic inflammatory processes and malignancy (Birkedal-
Hansen et al, 1993). Their role in malignancy is highlighted by
the number of cancers that have elevated MMP levels, including
breast (Basset et al, 1990), prostatic (Pajouh et al, 1991), gastric
(Nomura et al, 1995), ovarian (Campo et al, 1992), pancreatic
(Gress et al, 1995; Bramhall et al, 1997), and colorectal disease
(Hewitt et al, 1991; Gallegos et al, 1995). This led to great interest
in development of MMP inhibitors as potential tumour-control
agents. Unfortunately, clinical trials have failed to demonstrate
successful curtailment of tumour progression (Greenwald, 1999;
Steward, 1999). Nevertheless their elevation in a range of cancers
prompted us to address the possibility that their levels may be
elevated in the serum of patients with colorectal cancer.
AIMS
The aims of this study were to (1) investigate the prophetic role of
elevated serum matrix metalloproteinase 9 (sMMP-9) levels in
identifying colorectal neoplasia within a symptomatic cohort and
(2) assign and quantify relative risk of neoplasia based on serum
analysis, in order to prioritise for, or even exclude from, further
investigation.
MATERIALS AND METHODS
Ethical approval was provided by South Birmingham REC and
University Hospital Birmingham NHS Trust R&D office (857/04;
RRK2544). All adult patients referred to a specialist colorectal
clinic over a 12-month period were invited to participate. After
giving informed consent, study subjects donated a sample of
blood, which was encoded. All patients then were clinically
assessed by proforma-led history and physical examination
including rigid sigmoidoscopy. Protocol-driven invasive investiga-
tion ensued and patients were tracked to a definitive diagnosis.
Serum samples were analysed for MMP-9 concentration and
compared to decoded patient diagnoses. Diagnostic grouping were
coined to facilitate analysis (Table 1) and a hierarchy of diagnoses
was employed (data not shown) to express in simple terms the
most significant pathology identified.
Patients unable or unwilling to give informed consent were
excluded and referred for investigation as per clinic protocols.
Patients who did not attend for subsequent investigation were
excluded from the study if they did not respond to reminders
generated by the imaging department (independent of the study).
Table 1 Diagnostic coding
Coding
Diagnosis
Normal control 1
No abnormality detected on investigation (NAD) 2
Haemorrhoids 3
Irritable bowel syndrome 4
Diverticular disease 5
Inflammatory bowel disease 6
Other anal/colorectal non-neoplastic pathology 7
Other non-colorectal non-neoplastic pathology 8
Non-premalignant polyp (metaplastic) 9
Adenomatous polyp 10
Colorectal carcinoma 11
Non-colorectal malignancy (primary diagnosis) 12
Other ‘screenworthy’ pathology (non-neoplastic) 13
Diagnostic grouping
Normal/no screenworthy pathology 1, 2, 3, 4, 5, 6, 7, 8, 9
Normal/no detectable disease 1, 2
Benign non-screenworthy pathology 2, 3, 4, 5, 6, 7, 8, 9
Colorectal adenomatous polyp 10
Colorectal malignancy 11
Colorectal malignant and premalignant 10, 11
Screenworthy pathology 10, 11, 12, 13
Normal control: laboratory disease-free volunteers. NAD: patients without positive
findings on colorectal imaging, and includes patients with self-limiting symptoms as
well as asymptomatic individuals requesting screening investigation for poor family
histories in whom no lesion was identified. Diverticular disease: patients with proven
diverticulosis and symptoms compatible with the clinical manifestations of the
condition, without evidence of septic complications. Inflammatory bowel disease
includes Crohn’s disease, ulcerative colitis, and non-specific colitis. Other anal/
colorectal non-neoplastic pathology includes conditions such as fissure and non-
specific pruritis ani. Other non-colorectal non-neoplastic pathology includes diverse
conditions such as coeliac disease, ovarian cystic disease, and vascular conditions.
Metaplastic polyps were considered to have no malignant potential, while
adenomatous polyps were considered potentially pre-malignant entities. Non-
colorectal malignancies included those of ovarian, gastric, haematological, and renal
origin. Screenworthy pathology (code ‘13’) includes diverticular strictures requiring
surgical intervention for diagnostic discrimination from malignancy.
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sSerum preparation
Blood was harvested by single venepuncture, into plain tubes using
the proprietary Vacutainer
s system, prior to eliciting histories or
physical examination. After clotting, serum was separated
(centrifuged at 2000g) and aliquoted to polyethylene Eppendorf
vials for storage at  801C until analysis.
MMP-9 ELISA
MMP-9 ELISA kits (R&D Systems, UK) were used according to the
manufacturer’s instructions. Serum samples were diluted 100-fold
in assay buffer. All assays were performed in duplicate on each of
two enzyme-linked immuno-sorbant assay (ELISA) plates assayed
2 weeks apart, and concordance within 10% for all four wells was
required. Serum MMP-9 (sMMP-9) concentrations from ‘disease-
free normal control’ samples declined with advancing age (n¼46;
R
2¼0.027) and, therefore, age-specific predicted (expected)
sMMP-9 were generated. Ratios of observed/expected values were
calculated; a ratio of less or equal to 1 was considered normal,
while ratios above 1 were considered pathologically elevated. A
sample was denoted ‘positive’ if the observed to expected ratio
exceeded 1, and a similar prospective prediction of the presence of
underlying colorectal neoplasia was declared, prior to breaking the
identifying sample code. The underlying definitive diagnosis was
compared to the prospective prediction and accuracy recorded.
Total sMMP-9 concentrations were also recorded and mapped to
diagnostic group.
Statistical analyses
To identify associations in the data, Pearson’s w
2 test was used for
categorical variables. The non-parametric Wilcoxon two-sample
test (W) and Kruskal–Wallis test (KW) for more than two samples
were used to compare groups of continuous measurements. Odds
ratios (OR) were calculated to determine the association between
exposure to possible risk factors and outcome. ORs, adjusted for
all other predictive variables, were derived from logistic regression
analyses. Non-neoplastic diagnoses were combined (non-
neoplastic group), as were pre-malignant adenomas and colorectal
carcinomas ((pre-) malignant group) in order to devise a logistic
regression model to ‘predict’ patients with (pre-) malignant
disease. All available factors were considered in the logistic
regression analyses (gender, age, sMMP-9 level (ngml
 1) under a
log transformation, family history, rectal bleeding, altered bowel
habit, abdominal pain, weight loss, and smoking history). Logistic
regression analyses using backward elimination of variables were
performed using a 5% significance level to determine independent
factors for prediction of those with pre-malignant or established
malignant disease. Model accuracy was calculated and sensitivity,
specificity, proportion of false positives, and negatives and overall
percentage of correct predictions were presented. The probability
cut-point was chosen to balance sensitivity and specificity.
RESULTS
Serum MMP-9 concentration analysis
A total of 365 patients were seen by a single clinician in the QED
(Quick and Early Diagnosis) specialist colorectal clinic over a 12-
month period. Onward referral for further investigation occurred
in 332 cases. Informed and consenting patients donated serum for
analysis. Eighteen patients declined to participate and 14 patients
did not attend for their investigations. Three hundred patients with
a definitive diagnosis (achieved largely by double-contrast enema)
and matched serum samples were therefore enrolled in the
serological arm of this study. These comprised 134 males (median
(IQR) age: 62 (52–71) years) and 166 females (median (IQR) age:
64 (51–76) years). Twenty-seven significant adenomas (multiple
43, severe dysplasia, 41cm diameter with predominant villous
component) and 63 malignancies were identified in the study
population. All Duke’s stages were represented in the population
(Stage A: 13 (20.9); B; 21 (33.9); C: 20 (32.3); D: 9 (12.9%)). Forty-
six normal controls (healthy laboratory and hospital staff
including retired voluntary workers) were recruited and bled (18
males, median age 52 years (inter-quartile range 46–65); 28
females, median age 62 years (inter-quartile range 51–73)).
Observed to predicted ratios
There was a wide variation in ELISA-determined sMMP-9
concentration. Nevertheless a median sMMP-9 control value of
261ngml
 1 was obtained (IQR: 105–520; mean¼340) in these 46
patients. Sample repeat analysis after storage (at  801C) did not
affect detected MMP9 concentrations. Several non-neoplastic
conditions were diagnosed in the sample group including
haemorrhoids, diverticular disease, irritable bowel syndrome,
and colitis (Table 2). In each of these individual conditions
the mean sMMP-9 concentration was not significantly greater than the
control value. In contrast, patients with pre-malignant adenomas
or colorectal carcinoma had significantly elevated sMMP-9 levels.
Ratios of observed to predicted values of sMMP-9 concentration,
corrected for patient age, demonstrated the ability to differentiate
between non-neoplastic and neoplastic disease (Figure 1).
Significant differences were demonstrable between sMMP9
Table 2 Non-neoplastic conditions represented in symptomatic patient
group
Diagnostic category n %
NAD 46 23
Haemorrhoids 25 12
Diverticular disease 85 42
Irritable bowel syndrome 7 3
Inflammatory bowel disease 14 7
Other colorectal non-neoplastic 13 6
Non-colorectal non-neoplastic 10 5
Metaplastic polyp 5 2
Total 205 100
Abbreviation: NAD¼no abnormality detected.
Observed/predicted maximum serum
MMP9 concentration
Control
NAD
Non-neoplastic
Adenoma
Carcinoma
All neoplasia
0
1
2
3
4
R
a
t
i
o
P<0.0001
Mean, 95% CI
Figure 1 Observed to predicted maximum serum matrix metallopro-
teinase 9 (sMMP-9) concentrations. Highly significant differences between
non-neoplastic and neoplastic conditions demonstrated.
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(Po0.0001). No statistically significant differences were identified
between controls and no abnormality detected (NAD) groups
(P¼0.2794), or between NAD groups and non-neoplastic patients
(P¼0.1490).
A patient-specific prediction of the presence or absence of
screenworthy pathology (see Table 1) was made based on the
observed to predicted ratio of sMMP-9. This was compared to
definitive diagnoses to ascertain accuracy of prediction, results of
which can be seen in Table 3. The overall accuracy of this
prediction was 61.0%, with a false negative rate of 1.3%; one lesion
was visible in the mid-rectum giving an effective clinical false-
negative rate of 1%. However, this was at the expense of an
increased false-positive rate of 37.7%. Positive and negative
predictive values were 44.6 and 95.8%, respectively. It is
particularly noteworthy that no pre-malignant lesions were over-
looked by this method. The raw cancer rate in our referred study
population was 22.7%, rising to 31.4% in those with a positive
serological ratio; similarly the pre-malignant adenoma rate rose
from 9 to 13.2% under the same conditions. Overall (pre)-
malignant lesion rates rose from 31.7 to 44.6% (a 40.7% increase).
Restriction of invasive investigations to only those with positive
serology could reduce imaging requirements by 32%, risking
overlooking four lesions, of which one was visible in the mid-
rectum, or 4.2% of screenworthy pathology. Alternatively,
prioritising the patients for investigation on the basis of serological
results may reduce time to detection in those with positive invasive
investigations.
Absolute serum MMP-9 concentrations
Progressing from individual patient predictions, an assessment
was made of the probability of specific levels of sMMP-9, in groups
with particular characteristics, indicating the presence of a
screenworthy lesion. Additionally the contribution of each of
several variant factors to the risk of harbouring colorectal (pre)-
malignant disease was calculated.
Measured sMMP-9 concentrations were recorded against multi-
ple factors postulated potentially relevant to modification of risk of
colorectal neoplasia. Subjects were categorised as symptomatic
non-neoplastic (n¼205) including 46 normal controls, or color-
ectal (pre)-malignant (n¼95). Factors considered in logistic
regression analysis included sMMP-9 level (under a log transfor-
mation), age, gender, smoking history (never vs ever), family
history (negative vs positive), rectal bleeding (negative vs positive),
persistent altered bowel habit (negative vs positive), unexplained
abdominal pain (negative vs positive), and unexplained weight loss
(negative vs positive). The median sMMP-9 levels between the
various non-neoplastic and control categories (see Table 1) did not
significantly differ (KW w
2¼5.69, P¼0.58) and groups were
combined as the non- (pre)-malignant group (n¼205). sMMP-9
concentrations in the pre-malignant group (n¼27) and the
colorectal malignant group (n¼59) were statistically similar
(KW w
2¼3.38, P¼0.34), confirming suitability for their combina-
tion as a single group.
The risk of neoplastic disease at univariate analysis was
significantly associated with increased age, male gender, increased
sMMP-9, and paucity of index symptoms, other than weight loss
(Table 4). Logistic regression analysis sought to identify the
contribution of each variable to the risk of neoplastic disease
multivariably utilising the complete data set of 300 patients in the
final logistic regression model, including 95 patients with
malignant or pre-malignant pathology. The final model identified
sMMP-9 as the single most significant predictor of (pre)-malignant
disease (w
2¼38.33, Po0.001). Other significant independent
predictors of neoplastic disease identified were advancing age
(w
2¼11.25, Po0.001), male gender (w
2¼8.73, P¼0.003), a
negative smoking history (w
2¼4.87, P¼0.027), absence of
abdominal pain (w
2¼4.72, P¼0.030), and increased weight loss
(w
2¼4.70, P¼0.030). The other three variables (rectal bleeding,
altered bowel habit, or family history) did not achieve statistical
significance for inclusion, in keeping with the findings of the
barium enema study previously described.
Furthermore, the risk of being in the (pre)-malignant group,
attributable to a 1-unit increase in log(sMMP-9) concentration is
estimated as a 5.09-fold risk (95% confidence interval (CI): 3.04,
8.51). The difference in median sMMP-9 concentrations between
non-neoplastic and (pre)-malignant groups was 443ngml
 1.
Similar calculations are possible for aging patients, who demon-
strate a 4% increased risk per additional year (95% CI: 2–7%)
generating a risk elevation of 66% per advancing decade of life.
The model estimated increased risks of neoplastic disease for men
(OR¼2.52; 95% CI: 1.37, 4.66), non-smokers (OR¼0.48; 95% CI:
0.25, 0.92), absence of abdominal pain (OR¼0.49; 95% CI: 0.26,
0.93), and weight loss (OR¼2.60; 95% CI: 1.10, 6.15) (Table 5).
A probability equation can be derived from data held in Table 5
to enable calculation of the probability of an individual patient,
with defined characteristics, being included in the (pre)-malignant
group (Figure 2).
Moderation of the probability threshold denoting inclusion in
the (pre)-malignant group defines the accuracy of the prediction
generated.
If a probability threshold to balance sensitivity and specificity is
assumed, the model accurately predicts inclusion or exclusion
from this group in 77.3% of patients, for this sample. Sensitivity
and specificity are 77.9 and 77.1%, respectively. However, falsely
negative predictions are produced in 21 individuals (11.7% of
negative predictions, 7.0% of all predictions). Falsely positive
predictions are derived in 47 patients (38.8% of positive
predictions, 15.7% of all predictions).
Patient groups may be defined based on age, gender, smoking
history, abdominal pain, weight loss, and ultimately sMMP-9
concentration to provide estimated risks of colorectal neoplasia.
In the best case scenario, a 32-year old, female smoker with
abdominal pain, no weight loss, and an sMMP-9 concentration of
263, would have a calculated probability of colorectal neoplasia of
1.1%. The same woman with an sMMP-9 concentration of
1025ngml
 1 would have an eightfold elevation of her risk
(8.9%). In the worst case scenario, a 79-year old, male, non-
smoker with no abdominal pain, increased weight loss and an
sMMP-9 level of 895, would have a calculated risk of colorectal
neoplasia of 93.5%.
CONCLUSIONS AND DISCUSSION
Serum MMP-9 estimation may facilitate stratifying patients
referred to a specialist rapid access colorectal cancer unit into
low- or high-risk cohorts, when analysed by ELISA. If our results
are validated in further studies, individualised prediction of the
risk of colorectal neoplasia may be inferred by comparison to local
Table 3 Comparison of prediction based on observed to predicted
serum MMP-9 ratios to presence or absence of screenworthy pathology
Observed/predicted ratio
+ve (41.0)  ve (p1.0)
SWP
Yes 91 4 95
No 113 92 205
204 96 300
Abbreviation: SWP¼screenworthy pathology. Sensitivity: 44.6%, specificity: 95.8%,
positive predictive value: 95.8%, negative predictive value: 44.9%.
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excess of 76%, far exceeding that obtainable by the primary non-
invasive stratification tool in current use in the United Kingdom
(guaiac FOBT). While more specific methods of faecal occult blood
detection are available (including immunological iFOBT, eg,
Hemeselect
s and Quickview
s) their increased cost has, to date,
precluded use in the bowel screening programme. Heightened
sensitivity may be obtained by faecal DNA analysis (PreGen-
Plus
s) which improves detection of colorectal neoplasia from 12.9
to 51.6% compared to standard guaiac-based FOBT (Imperiale
et al, 2004), but these techniques are expensive ($575/test at
commercial rates) and their use is, at present, limited to the
research setting.
Quantification of the probability of neoplasia is modifiable
according to local preference. If exclusion of falsely negative test
results is desirable in order to reduce the total burden of invasive
imaging, sensitivity may be as high as 96.4% (rising to 99.7% in
combination with clinical assessment), by altering the probability
threshold calculations to favour sensitivity. If conversely, simple
stratification is desirable to prioritise imaging appointments,
modifying the probability threshold to 0.3 increases the positive
imaging rate from 29 to 57%.
Secondary ‘sieving’ of patients with positive FOBTs returned in
the screening round of the national colorectal cancer screening
programme could be performed by means of ELISA quantification
of sMMP-9. Negative serum samples could be excluded from
confirmatory colonoscopy, significantly reducing the burden on
this service. The cost savings generated could amount to a sizeable
proportion of the running costs of the national FOBT screening
Table 4 Univariate analysis of diagnostic category
Diagnostic category
(Pre)-malignant n¼95 (%) Non (pre)-malignant n¼205 (%) Odds ratio (95% CI)
Sex
Female 43 (45%) 123 (60%) 1 *
Male 52 (55%) 82 (40%) 1.81 (1.11, 2.96)
Smoker
Never 71 (75%) 114 (56%) 1 **
Ever 24 (25%) 91 (44%) 0.42 (0.25, 0.73)
Family history
No 89 (94%) 187 (91%) 1
Yes 6 (6%) 18 (9%) 0.70 (0.27, 1.83)
Bleeding
No 55 (58%) 89 (43%) 1 *
Yes 40 (42%) 116 (57%) 0.56 (0.34, 0.91)
Abdominal pain
No 68 (72%) 101 (49%) 1 ***
Yes 27 (28%) 104 (51%) 0.39 (0.28, 0.65)
Weight loss
No 73 (77%) 184 (90%) 1 **
Yes 22 (23%) 21 (10%) 2.64 (1.37, 5.09)
Altered bowel habit
No 55 (58%) 92 (45%) 1 *
Yes 40 (42%) 113 (55%) 0.59 (0.36, 0.97)
n Median (IQR) Median (IQR) P (Wilcoxon)
Age 300 70 (56, 78) 61 (50, 70) Po0.001
MMP-9 300 799 (514, 1086) 356 (160, 592) Po0.001
Abbreviations: CI¼confidence interval; MMP-9¼ metalloproteinase 9. ***Po0.001, **Po0.01, *Po0.05 when using w
2 analysis. Odds ratios are given for likelihood of (pre)-
malignant disease, for any given univariate discriminator.
Table 5 Logistic regression model for the prediction of (pre)-malignant
disease
Variable Calculation bv
2 P Odds ratio (95% CI)
Intercept —  13.427 44.03 o0.001 —
LogMMP-9 Continuous 1.626 38.33 o0.001 5.09 (3.04, 8.51)
Age Continuous 0.040 11.25 o0.001 1.04 (1.02, 1.07)
Sex Female vs male 0.925 8.73 0.003 2.52 (1.37, 4.66)
Smoking history Never vs ever  0.731 4.87 0.027 0.48 (0.25, 0.92)
Abdominal pain No vs yes  0.718 4.72 0.030 0.49 (0.26, 0.93)
Weight loss No vs yes 0.954 4.70 0.030 2.60 (1.10, 6.15)
Abbreviation: CI¼confidence interval. Adjusted R
2¼0.44.
Probability of inclusion in (pre)-malignant diagnostic category
  Z = –13.427 + 1.626(log MMP-9) + 0.040(age) + 0.925(sex) – 0.731(smoking history) – 
0.718(abdominal pain) + 0.954(weight loss) 
P =
exp(Z)
1+exp(Z)
Sex: 0=female, 1=male 
Smoking history: 0=never, 1=ever 
Abdominal pain: 0=no, 1=yes 
Weight loss: 0=no, 1=yes 
Figure 2 Logistic regression equations for calculation of individual risk.
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sprogramme. Furthermore, avoidance of unnecessary colonoscopy
has the added benefit of reducing patient anxiety and potential for
iatrogenic morbidity and mortality, with associated secondary cost
savings accrued.
Limitations of this method of risk stratification include the
introduction of human error into the assay protocol, resulting in
inaccurate ELISA data with potentially damaging results. However,
duplication and quality control concordance checks could help to
minimise this risk and automation would reduce technical
variations between assay plates.
This study was undertaken in a selected population with a high
prevalence of malignancy; the usefulness of sMMP9 as a primary
or secondary screening test may vary in population with different
prevalence of disease. Nevertheless, this study suggests that
sMMP9 may have potential application: (1) normal sMMP9 levels
may be a means of identifying those at low risk of malignant
disease and avoiding the need for invasive investigations and (2)
raised sMMP9 levels may be a means of identifying those at
increased risk of malignancy. Further research in larger, more
representative populations is required to determine the usefulness
of sMMP9 in stratifying both symptomatic and asymptomatic
populations and determining any regional or ethnic variations in
normal sMMP-9 profiles. This preliminary work has informed
further ongoing work aiming to evaluate the role of sMMP9 in
detecting (pre)-malignant disease in more typical populations
(Ryan et al, 2006; Wilson et al, 2006).
The detection of colorectal neoplasia by this method is not
infallible, but this work demonstrates that it has the potential to
add to existing methodologies. It identifies that the capability
exists not only for detection of established malignancy, but also for
pre-malignant lesions with the same accuracy as their invasive
counterparts. No other methods currently in the public domain
have shown the ability to identify colorectal adenomas by non-
invasive means with this degree of accuracy.
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